

Remarks

Claim 1 is pending in this application.

Claims 2-39 have been canceled without prejudice.

Claim 1 has been amended to specify that the FAAH is complexed with methoxy arachidonyl fluorophosphate, to specify the sequence of the FAAH, and to delineate the point group and unit cell dimensions of the crystals of the complex. Support for the amendment can be found in the specification on pages 13-16. No new matter is added by this amendment.

Objections to the Specification.

The specification was objected to for informalities in the listing of sequence identifiers. In response, the specification has been amended to correct these informalities e.g., by making reference to the specified residues of SEQ ID NO: 1. The specification also has been amended to correct some inadvertent errors in identifying the Figures. The description of Figure 4 was also amended to refer to the sequence shown in the figure. The specification is now believed to be in conformity with the sequence rules. No new matter is added by these amendments.

Rejections Under 35 U.S.C. §112.

Claim 1 stands rejected under the first paragraph of 35 U.S.C. §112 as allegedly failing to comply with the written description requirement. Present claim 1 is directed to the three species of crystalline FAAH complexes that are specifically disclosed in the application. Accordingly, this ground for rejection should be withdrawn.

Claim 1 also stands rejected under the first paragraph of 35 U.S.C. §112 as allegedly failing to comply with the enablement requirement. This ground for rejection should be withdrawn as well, for the same reasons as the written description rejection.

Rejections Under 35 U.S.C. §102(a).

Claim 1 stands rejected as being anticipated by the dissertation of Hanson. Applicants submit that this is the inventors' own work, published less than a year before the filing date of the priority provisional application. Accordingly, this publication is not available as prior art under

Section 102(a), because it is not "by another."

Rejections Under 35 U.S.C. §103(a).

Claim 1 stands rejected under 35 U.S.C. §103(a) as allegedly being obvious over Santarsiero *et al.* in view of Cravatt *et al.*; and as allegedly being obvious over Patricelli *et al.* in view of the Amersham Protein Purification Handbook. These rejections are unwarranted.

The applied Santarsiero and Cravatt references relate to crystallized, full length FAAH, not to the crystallized complex of truncated FAAH with methoxy arachidonyl fluorophosphate that is presently claimed. There is nothing in the applied reference that teaches or suggests the presently claimed crystallized complex, much less a crystallized complex having the space groups and unit cell dimensions set forth in the claim.

Similarly, there is nothing in the Patricelli *et al.* and Amersham references that teaches or suggests the crystallized complex of truncated FAAH with methoxy arachidonyl fluorophosphate, or the space groups and unit cell dimensions set forth in claim 1. Thus, these rejections should be withdrawn.

Conclusion.

Reconsideration, allowance of all claims, and early passage of the application to issue is solicited.

Respectfully submitted,

April 15, 2009

By 
Robert J. Ross (Reg. No. 45,058)

OLSON & CEPURITIS, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180